Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) and LENVIMA - (LEAP-002) | Unresectable hepatocellular carcinoma (uHCC) | Phase 3 | Intravenous | Oncology | |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) - (KEYNOTE-921) | Metastatic castration-resistant prostate cancer (mCRPC) | Phase 3 | Intravenous | Oncology | |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) - (KEYNOTE-412) | Head and neck squamous cell carcinoma (HNSCC) | Phase 3 | Intravenous | Oncology | |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) - (KEYNOTE-091) | Non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) in Combination with LYNPARZA (olaparib) - (KEYLYNK-010) | Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Intravenous | Oncology | |
| Merck & Company Inc. | BAVENCIO (avelumab) - (JAVELIN Lung 100) | Metastatic non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) with Sorafenib - (KEYNOTE-394) | Hepatocellular Carcinoma (HCC) | Phase 3 | Intravenous | Oncology | |
| Merck & Company Inc. | Islatravir (MK-8591-022) - (IMPOWER 22) | HIV | Phase 3 | Oral | Anti-HIV |
